Perioperative Nivolumab Beneficial for Resectable NSCLC
Perioperative nivolumab showed event-free survival benefit from time of surgery compared with neoadjuvant nivolumab
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.